Fujifilm/MediVector antiviral favipiravir advances in Ebola
This article was originally published in Scrip
Executive Summary
Favipiravir (T-705), an antiviral drug that initially was developed by Fujifilm and its US subsidiary MediVector to fight seasonal influenza, is advancing into clinical testing in Guinea as a treatment for Ebola – trials whose preliminary results could be available by as early as year end, a company official said on 11 November.